Clinical DevelopmentThe safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Financial ResourcesTransCode ended 2024 with $5.8M in cash and equivalents, which does not include the recent $8.8M equity raise, assumed sufficient to fund operations into 2026.
Strategic PartnershipsThe company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.